According to the Legislative Budget Board (LBB), the fiscal implications of HB 4014 indicate a projected negative impact of $1,000,000 to General Revenue during the 2026 fiscal year. This cost arises from the requirement that the Health and Human Services Commission (HHSC) conduct a comprehensive study on the therapeutic use of psychedelics, specifically MDMA, psilocybin, and ketamine, for the treatment of post-traumatic stress disorder (PTSD), depression, and co-occurring mental health conditions.

HHSC reports that it lacks internal subject matter expertise in psychedelic therapies and would therefore need to contract with an external research institution to fulfill the study requirements. For the purpose of fiscal estimation, the agency anticipates partnering with Baylor College of Medicine based on its prior collaborations with the institution. The projected $1 million figure is derived from previous costs associated with similar contract-based studies, which would include the literature review, data collection, stakeholder consultations, and the drafting of a final report.

Importantly, the bill itself does not include an appropriation. However, it would provide the legal authority for the legislature to appropriate funds for implementation. The bill also allows HHSC to pursue external funding sources such as federal grants, gifts, or donations, which could potentially offset the cost to the state if successful. No significant fiscal impact is expected at the local government level.

In sum, the bill would result in a one-time cost of $1 million in fiscal year 2026, with no continuing fiscal obligations in subsequent years. While relatively modest in scale, this fiscal impact is contingent on legislative appropriation or the availability of alternative funding sources.

HB 4014 proposes a well-intended but ultimately unnecessary and potentially wasteful state-funded study on the use of psychedelic therapies for the treatment of mental health conditions like PTSD and depression. While these therapies, specifically MDMA, psilocybin, and ketamine, have shown strong potential in treating serious conditions, their efficacy has already been extensively documented in FDA-approved clinical trials and peer-reviewed academic research. Therefore, this bill risks spending taxpayer dollars to reaffirm what is already widely known.

The bill calls for the Health and Human Services Commission (HHSC) to conduct a new study, despite HHSC acknowledging it lacks subject matter expertise in this area. As a result, the agency would need to outsource the project to an external institution, likely Baylor College of Medicine, at an estimated cost of $1 million in General Revenue during fiscal year 2026. Although the bill permits HHSC to solicit external funding and only mandates implementation if the legislature appropriates money for the study, it still creates a statutory foundation for future expenditures and programmatic growth that may be difficult to control once established.

The concern is not with the underlying goal, allowing Texans access to promising treatments, but rather with the method. A taxpayer-funded study, duplicating existing research, represents a classic example of government overreach. It risks becoming a "solution in search of a problem," providing no actionable value while potentially serving as justification for future regulatory frameworks, programs, or spending. Instead of using time and resources on another study, the state should focus on removing legal barriers and preparing for the lawful use of these therapies once they receive federal approval.

Furthermore, this study could be interpreted as a placeholder for future government action that may lead to new licensing regimes, regulations, or oversight structures, none of which are guaranteed to respect individual liberty or fiscal restraint. In light of those risks, and given the ample data already available from credible sources, Texas Policy Research recommends that lawmakers vote NO on HB 4014 as a vote for responsible governance, budget discipline, and targeted action over redundant process.

In conclusion, while the therapeutic use of psychedelic substances may deserve serious policy consideration, this bill’s approach, mandating a state-run study with vague implementation boundaries, does not align with the principles of limited government or efficient use of public funds. The better path forward would be to monitor FDA approvals and prepare for access through direct, lean, and rights-respecting legislative action.

• Individual Liberty: On the surface, the bill engages positively with the principle of individual liberty by recognizing the need to explore innovative mental health treatments. It acknowledges therapies that could offer relief to veterans and others suffering from PTSD and depression, conditions often underserved by current medical systems. However, the bill does not expand access or legal rights to use these therapies. Instead, it merely proposes a government study, thereby delaying actual liberty-enhancing reforms. In this way, it can be seen as an indirect or symbolic nod to individual liberty without delivering tangible changes.
• Personal Responsibility: The principle of personal responsibility is not meaningfully advanced or hindered by the bill. While some may argue that allowing access to psychedelic therapies empowers individuals to take control of their mental health, this bill does not legalize or authorize such access; it only studies it. Therefore, the bill does not materially increase an individual's ability to make responsible health decisions, nor does it trust individuals to assess risk based on the body of existing evidence.
• Free Enterprise: The bill could eventually have implications for free enterprise, though not directly. By tasking a state agency (HHSC) with managing the research process and possibly recommending best practices or regulatory frameworks, the bill may lay the groundwork for future state-driven licensing schemes or restrictive medical gatekeeping. If improperly implemented later, these outcomes could favor entrenched institutions or create regulatory barriers to market entry for independent providers. In this way, the bill may unintentionally chill the kind of market-based innovation that would otherwise emerge once these therapies are federally approved.
• Private Property Rights: The bill does not address or affect private property rights in any meaningful way.
• Limited Government: This is where the bill has the most direct and concerning effect. Though the bill includes some fiscal safeguards, such as only requiring implementation if funds are appropriated and allowing outside funding, it still creates a legal structure for expanding government activity. It authorizes a taxpayer-funded study that could become a precursor to additional spending, new programs, or increased state control over emerging therapies. For those who believe government should not insert itself where private research and federal agencies are already active, this represents unnecessary and duplicative bureaucracy. In this respect, the bill is in tension with the principle of limited government, as it uses taxpayer dollars to explore territory already well covered by private and federal efforts.

• SB 3005 (Same As)